Académique Documents
Professionnel Documents
Culture Documents
EDUCATIONAL AIMS
The reader will be able to:
Understand the pathophysiology of paediatric status asthmaticus
Assess the severity of an asthma exacerbation,
Implement different treatment strategies for severe asthma.
A R T I C L E I N F O
S U M M A R Y
Keywords:
Paediatric status asthmaticus
Pathophysiology
Assessment
Treatment
Recent literature on paediatric status asthmaticus (PSA) conrms an increasing percentage of admissions
to paediatric intensive care units. PSA is a medical emergency that can be fatal and needs careful and
prompt intervention. The severity of PSA is mainly determined by clinical judgement of signs and
symptoms. Peak ow measurements and serial lung function measurements are not reliable in PSA.
Validated clinically useful instruments are lacking. The three main factors that are involved in the
pathophysiology of PSA, bronchoconstriction, mucus plugging and airway inammation need to be
addressed to optimise treatment. Initial therapies include supplementation of oxygen, repetitive
administration of rapid acting b2-agonists, inhaled anticholinergics in combination with systemic
glucocorticosteroids and intravenous magnesium sulphate. Additional treatment modalities may include
methylxanthines, DNase, ketamine, sodium bicarbonate, heliox, epinephrine, non-invasive respiratory
support, mechanical ventilation and inhalational anaesthetics.
2013 Elsevier Ltd. All rights reserved.
INTRODUCTION
Paediatric status asthmaticus (PSA) is a medical emergency
warranting prompt recognition and intervention. A status asthmaticus or severe asthma exacerbation is dened as an acute
episode that does not respond to standard treatment with short
acting b2-agonists and corticosteroids, although a large variation
exists in this denition between authors.13 In other denitions,
need for hospitalisation, emergency room visit or decline in peak
expiratory ow (PEF) is also taken into account. PSA can result in
respiratory insufciency as well as circulatory failure and is
potentially life-threatening. The incidence of PSA has to be viewed
against the background of the total number of asthmatic patients.4
In the United States, the number of patients with asthma
increased from 20.3 million to 25 million between 2009 and 2011.
In 2009 the prevalence among children (less than 18 years old) was
* Corresponding author. Tel.: +0032/496068751; fax: +0032/2810292.
E-mail address: murielkoninckx@gmail.com (M. Koninckx).
1526-0542/$ see front matter 2013 Elsevier Ltd. All rights reserved.
http://dx.doi.org/10.1016/j.prrv.2013.03.003
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
Figure 1. Number and rate* of asthma deaths, by year and International Classication
of Diseasesy (ICD) United States, 1980-2004.
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
Pulse oximetry
Measuring SaO2 is an important tool to determine asthma
severity, but always in combination with other parameters. Initial
SaO2 <91% or SaO2 unresponsive to oxygen treatment are related
to hospital admission and outcome.20,21 The cut-off value of 91% is
somewhat arbitrary and needs to be seen in the context of the
whole patient.21 Low oxygen saturations and hypoxia are the
consequence of V/Q mismatch caused by mucus plugging,
bronchoconstriction and bronchial inammation with a low
degree of intrapulmonary shunting.
Clinical scoring systems
Severity is predominantly assessed by applying clinical judgement, based on different signs and symptoms, including respiratory effort, pulse rate and the presence of pulsus paradoxus in
combination with measurements of gas exchange (Table 1).
Warning signs of imminent respiratory arrest should be observed
closely and warrant immediate PICU care and intervention.
A clinically useful and simple (but unvalidated) tool to assess
severity of PSA is shown in Table 2.22 This tool results in a score
between 5 and 15 which can be repeated on a regular basis and can
help assess the effect of therapy. The paediatric asthma severity
score (PASS) is based on assessment of three clinical ndings and
validated in children.23 It is a three item score where every item is
scored as none or mild (0 points), moderate (1 point) or severe (2
points). Minimum score is 0, maximum score is 6. The items scored
Table 1
Clinical judgement
Classication of severity of an asthma exacerbation
Symptoms
Mild
Moderate
Severe
Imminent Respiratory
Arrest
Dyspnoea
When walking
At rest (infant:
stops drinking)
Gasping
Talks in:
Alertness:
Signs at physical examination
Breathing frequency
(awake patient)
Sentences
Can be agitated
Words
Most often agitated
None
Decreased or confused
Increased
Pulsus paradoxus
Fluctuation of pulse pressure
between in- and expiration.
Gas exchange
SaO2 (room air)
PaCO2
PaO2
Increased
Normal breathing
frequency in children
Age
< 2 months
2-12 months
1-5 years
6-8 years
Normal frequency:
(mean)
< 48/minute
< 42/minute
< 28/minute
< 24/minute
Often
Usually
Normal pulse:
80180
75150
60120
Absent
< 10 mm Hg
Can be present
1025 mm Hg
Often
2040 mm Hg (child)
> 95%
< 5.6 kPa
Normal
91-95%
< 5.6 kPa
> 8 kPa
< 91%
>= 5.6 kPa
< 8 kPa: possible cyanosis
100-120
Paradoxal thoracoabdominal
movements
Absent
Bradycardia
C.A. Camargo, G. Rachelefsky, M. Schatz. Managing asthma exacerbations in the emergency department. Summary of the national asthma education and prevention program
expert panel report 3 guidelines for the management of asthma exacerbations. Proc Am Thoracic Society 2009;6: 357366.83
The presence of several parameters, not necessarily all, gives an indication of the severity of status asthmaticus.
Many of these parameters have not been studied systematically, they only serve as guidance.
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
4
Table 2
Asthma score
VARIABLE
ASTHMA SCORING
1 point
2 points
3 points
34
30
26
23
>95 with room air
3539
3135
2730
2427
9095 with room air
Auscultation
expiratory wheezing
Retractions
Dyspnoea
none or intercostal
Speaks in sentences
or coos and babbles
SEVERITY OF ASTHMA
40
36
31
28
<90 with room air or
supplemental oxygen
Inspiratory and expiratoy
wheezing, diminished breath
sounds or both
Intercostal, substernal and supraclavicular
speaks in single words or short
phrases or grunts
MILD
MODERATE
SEVERE
>70
57
5070
811
<50
1215
F Qureshi, J Pestian, P Davis, A Zaritsky. Effect of nebulized ipratropium on the hospitalization rates of children with asthma. N Engl J Med 1998; 339: 10305.22
The overall asthma score (range 5 to 15 points) was calculated by adding the scores for each of ve variables: respiratory rate, oxygen saturation, auscultation, retractions and
dyspnoea. The overall asthma score was used to stratify children according to the severity of the disease.
*
When peak expiratory ow rate was known and reliable, it, rather than the asthma score, was used to stratify the children according to severity.
Oxygen
Asthma fatality is related to hypoxia. As respiratory arrest in
asthma has been associated with hypoxic asphyxia, oxygen is
advised as rst line therapy in acute severe (life-threatening)
asthma in the hospital setting.26 Oxygen also has a bronchodilating effect.17 Loss of respiratory drive through oxygen
delivery, associated with chronic hypercapnia, is very rare in
children and should not delay oxygen treatment. There are small
studies in children demonstrating that nebulisation of salbutamol without oxygen can cause profound hypoxaemia from
increased V/Q mismatch, but this could not be found in adult
studies.27
Short acting b2-agonists
Reversal of bronchoconstriction can be achieved by short acting
b2-agonists like salbutamol or terbutaline which are sympathomimetic agents with adrenergic effects like smooth muscle
relaxation resulting in bronchodilation. Inhaled short acting b2agonists have a local effect on the b-receptors in the bronchial
smooth muscle cells if air entry is sufcient. In cases of severe
bronchoconstriction, with mucus plugging and low tidal volumes,
the drug will not be able to reach the most affected areas. Even in
healthy subjects only a small fraction of the dose administered will
reach the bronchial receptors because of deposition in the pharynx
and swallowing with intestinal absorption leading to detectable
concentrations in plasma.28 Recent guidelines recommend continuous or repeated intermittent nebulised short acting b2agonists combined with oxygen in cases of severe hypoxaemia.29
Continuous nebulisation might be slightly better than intermittent
nebulisation, since it led to a shorter duration of hospital stay and a
decrease in bedside respiratory therapy care in one study.30
However, this study included only 17 patients. Depending on age
the dose of nebulised salbutamol is 2.5 mg (4 years) or 5 mg (>4
years) for intermittent administration. A metered dose inhaler
with spacer is equally effective as nebulisation, with the dose being
six inhalations [total of 600 mcg] or twelve inhalations [1200 mcg]
via spacer respectively.31 However, in contrast to adults, a recent
Cochrane review shows some advantages of an inhalation device
with holding chamber compared to a nebuliser, with a signicantly
shorter length of stay in the emergency department for the rst
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
Anticholinergic agents
These agents can decrease secretions, mucosal oedema and
reduce bronchomotor tone. Anticholinergic agents such as
ipratropium bromide give less bronchodilation and the effect
is slower compared to short acting b2-agonists. Adding multiple
doses of anticholinergics in moderate and severe acute asthma in
children to short acting b2-agonists has an additive effect. There
is a benet in terms of lung function and hospital admission.42
Recommended doses are 250-500 mg every 20 minutes for up to
three times, followed by administration every three hours if
necessary.43 In cases where salbutamol is given intravenously,
addition of ipratropium bromide does not have an additive
effect.44,45 Ipratropium bromide has a very low rate of absorption, implying that systemic side effects are rare. There are
reported cases of bronchoconstriction, but this adverse effect has
not been described when current isotonic ipratropium bromide
nebuliser solutions are used.46 In summary, ipratropium bromide
has no additional value when it is used in combination with
intravenous short acting b2-agonists in the intensive care
setting, but it can have a positive effect in the emergency
department.44,45
Steroids
In most cases of PSA, especially with failure to respond to
repeated short acting b2-agonists, steroids are added. Their most
important effect is controlling, suppressing and reversal of
inammation. They also potentiate the effect of b2-agonists on
smooth muscle relaxation, decrease b-agonist tachyphylaxis,
mucus production and microvascular permeability.47,48 The onset
of action of steroids is two to four hours with a maximum effect
after twelve hours. It is important to administer steroids early in
the disease course of PSA because this can lead to earlier discharge
and fewer relapses.49 Recommended doses of oral prednisone are
1-2 mg/kg/day with a maximum dose of 60 mg for 5 to 10 days.
Methylprednisolone is dosed 2 to 4 mg/kg/day with a maximum of
125 mg per day. Higher doses are not associated with better
effects.50 The same effect is achieved whether steroids are given
intravenously or orally, although in severely ill and dyspnoeic
children, the oral form is often difcult to administer. In mild to
moderate exacerbations a single dose of intramuscular dexamethasone has the same effect as a 5 day oral course with
prednisone.51
A study in 100 children with PSA that were randomised either
to oral prednisone 2 mg/kg or a single dose of 2 mg uticasone
through inhalation showed a higher FEV1 and a lower rate of
hospitalisation in the prednisone group.52 In children, adding high
doses of budesonide (1200-2000 mg) to systemic prednisone
(1 mg/kg) and nebulised albuterol can prevent or shorten
hospitalization.53 A more recent study concluded that adding a
single dose of 2 mg of budesonide to standard treatment of PSA did
not have a positive effect on asthma severity score or short term
outcome.54 Adverse effects of a short course treatment with
systemic steroids are mostly transient and can include hypertension, hyperglycaemia and mood disorders among others. These
reactions are especially described in high dose steroid pulse
therapy and chronic use. Overall in PSA, addition of systemic
steroids is recommended orally or intravenously. Conicting
results were reported on the addition of inhaled budesonide to
standard treatment of PSA.
Magnesium
Magnesium sulphate has a proven effect in status asthmaticus.
It works through smooth muscle relaxation secondary to inhibition
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
Ketamine
Ketamine has bronchodilating properties through increasing
circulating catecholamines after inhibition of the re-uptake of
noradrenaline in the presynaptic neurons. Ketamine was
successfully used to prevent intubation in two children with
status asthmaticus who received a loading dose of ketamine
(2 mg/kg) followed by continuous infusion of ketamine (2 mg/
kg/h).66 However, a study in 68 paediatric patients could not
demonstrate an additional benet of ketamine over conventional
emergency department therapy in PSA. A rather low loading
dose of 0.2 mg/kg followed by continuous infusion of 0.5 mg/kg/
h was used in this study.67 In refractory PSA ketamine might
have a place, especially when sedation and/or intubation are
considered.
Sodium bicarbonate
Respiratory or metabolic acidosis can be seen in PSA. The
presence of acidosis can diminish the effect of catecholamines.
Therefore, treatment of acidosis with sodium bicarbonate could be
benecial. Administration of sodium bicarbonate in 17 patients
with life threatening asthma admitted to the PICU showed a
signicant decrease in mean pCO2 and a signicant increase of
mean pH. Clinical improvement of respiratory distress and level of
consciousness was seen in individual patients.68 This small
retrospective study suggests sodium bicarbonate could be
considered in life threatening asthma with severe acidosis (pH
<7.2).
Heliox
Heliox is a mixture of 60% to 80% helium with 20 to 40% oxygen,
which often is insufcient to sufciently improve oxygenation in
hypoxic children. Heliox reaches lower and obstructed airways
more easily because of a lower resistance and less turbulent ow.69
In this way it can help to bring small particles, like salbutamol/
albuterol to the distal airways. A randomised controlled trial in 29
children with moderate to severe asthma exacerbations that
compared heliox driven continuous albuterol delivery to a 100%
oxygen driven delivery demonstrated that the heliox group had
better asthma scores.70 Other studies, however, showed opposite
results. A Cochrane review concluded that there is insufcient
evidence for the use of heliox in the standard treatment of acute
non-intubated asthma patients though it has proven its effect in
certain circumstances.71
Epinephrine (Adrenaline)
Epinephrine nebulisation was frequently used in asthma
patients in the 20th century. It has a b2-agonist effect with
relaxation of the bronchial smooth muscle cells. Additionally, it can
decrease airway oedema, inammation and mucus production
because of its effect on a-receptors. Intramuscular administration
of epinephrine is the rst choice in case of anaphylactic
asthma.72,73
Non-invasive respiratory support
Non-invasive ventilation (NIV) is increasingly used in PSA. In 72
episodes of NIV with PSA only 5 patients needed intubation. In the
other patients a signicant decline in heart rate, respiratory rate
and clinical asthma score was demonstrated during the rst
48 hours after start of NIV.74,75 Another randomised controlled
trial in children with lower airway obstruction also demonstrated
an improvement in clinical asthma score and respiratory rate
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
35. Browne GJ, Penna AS, Phung X, Soo M. Randomised trial of intravenous
salbutamol in early management of acute severe asthma in children. Lancet
1997;349:3015.
36. Shann F. Dose of intravenous infusions of terbutaline and salbutamol. Critical
Care Medicine 2000;28:217980.
37. Sellers WF, Messahel B. Rapidly repeated intravenous boluses of salbutamol for
acute severe asthma. Anaesthesia 2003;58:6803.
38. Bogie AL, Towne D, Luckett PM, Abramo TJ, Wiebe RA. Comparison of intravenous terbutaline versus normal saline in pediatric patients on continuous highdose nebulized albuterol for status asthmaticus. Pediatric Emergency Care
2007;23:35561.
39. Stephanopoulos DE, Monge R, Schell KH, Wyckoff P, Peterson BM. Continuous
intravenous terbutaline for pediatric status asthmaticus. Critical Care Medicine
1998;26:17448.
40. Carroll CL, Schramm CM. Protocol-based titration of intravenous terbutaline
decreases length of stay in pediatric status asthmaticus. Pediatric Pulmonology
2006;41:3506.
41. Carroll CL, Sala KA, Zucker AR, Schramm CM. Beta-adrenergic receptor polymorphisms associated with length of ICU stay in pediatric status asthmaticus.
Pediatric Pulmonology 2012;47:2339.
42. Plotnick LH, Ducharme FM. Should inhaled anticholinergics be added to beta2
agonists for treating acute childhood and adolescent asthma? A systematic
review. BMJ 1998;317:9717.
43. Health NIo. 3rd expert panel summary report from the national asthma
education and prevention programm 2007.
44. Browne GJ, Trieu L, Van Asperen P. Randomized, double-blind, placebo-controlled trial of intravenous salbutamol and nebulized ipratropium bromide in
early management of severe acute asthma in children presenting to an emergency department. Critical Care Medicine 2002;30:44853.
45. Rodrigo GJ, Castro-Rodriguez JA. Anticholinergics in the treatment of children
and adults with acute asthma: a systematic review with meta-analysis. Thorax
2005;60:7406.
46. Rafferty P, Beasley R, Howarth PH, Mann JS, Holgate ST. Bronchoconstriction
induced by nebulised ipratropium bromide: relation to the bromide ion. Br Med
J (Clin Res Ed) 1986;293:15389.
47. Barnes NC. Effects of corticosteroids in acute severe asthma. Thorax 1992;
47:5823.
48. Boschetto P, Rogers DF, Fabbri LM, Barnes PJ. Corticosteroid inhibition of airway
microvascular leakage. Am Rev Respir Dis 1991;143:6059.
49. Smith M, Iqbal S, Elliott TM, Everard M, Rowe BH. Corticosteroids for hospitalised children with acute asthma. Cochrane Database Syst Rev 2003;
CD002886.
50. Chipps BE, Murphy KR. Assessment and treatment of acute asthma in children. J
Pediatr 2005;147:28894.
51. Gries DM, Moftt DR, Pulos E, Carter ER. A single dose of intramuscularly
administered dexamethasone acetate is as effective as oral prednisone to treat
asthma exacerbations in young children. J Pediatr 2000;136:298303.
52. Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, et al. A
comparison of inhaled uticasone and oral prednisone for children with severe
acute asthma. N Engl J Med 2000;343:68994.
53. Schramm CM, Carroll CL. Advances in treating acute asthma exacerbations in
children. Curr Opin Pediatr 2009;21:32632.
54. Upham BD, Mollen CJ, Scarfone RJ, Seiden J, Chew A, Zorc JJ. Nebulized
budesonide added to standard pediatric emergency department treatment of
acute asthma: a randomized, double-blind trial. Acad Emerg Med 2011;18:
66573.
55. Skobeloff EM. An ion for the lungs. Acad Emerg Med 1996 Dec;3:10824.
56. Rowe B, Bretzlaff J, Bourdon C, Bota G, Camargo C. Magnesium sulfate is
effective for severe acute asthma treated in the emergency department. West
J Med 2000;172:96.
57. Cheuk DK, Chau TC, Lee SL. A meta-analysis on intravenous magnesium
sulphate for treating acute asthma. Arch Dis Child 2005;90:747.
58. Ciarallo L, Sauer AH, Shannon MW. Intravenous magnesium therapy for moderate to severe pediatric asthma: results of a randomized, placebo-controlled
trial. J Pediatr 1996;129:80914.
59. Devi RR KL, Singhi SC, Prasad R, Singh M. Intravenous magnesium sulfate in
acute severe asthma not responding to conventional therapy. Indian Pediatr.
1997; 34:38997.
60. Mitra A, Bassler D, Goodman K, Lasserson TJ, Ducharme FM. Intravenous
aminophylline for acute severe asthma in children over two years receiving
inhaled bronchodilators. Cochrane Database Syst Rev 2005. CD001276.
61. Wheeler DS, Jacobs BR, Kenreigh CA, Bean JA, Hutson TK, Brilli RJ. Theophylline
versus terbutaline in treating critically ill children with status asthmaticus: a
prospective, randomized, controlled trial. Pediatr Crit Care Med 2005;6:1427.
62. Rodrigo C, Rodrigo G. Treatment of acute asthma. Lack of therapeutic benet
and increase of the toxicity from aminophylline given in addition to high doses
of salbutamol delivered by metered-dose inhaler with a spacer. Chest
1994;106:10716.
63. Durward A, Forte V, Shemie SD. Resolution of mucus plugging and atelectasis
after intratracheal rhDNase therapy in a mechanically ventilated child with
refractory status asthmaticus. Critical Care Medicine 2000;28:5602.
64. Greally P. Human recombinant DNase for mucus plugging in status asthmaticus. Lancet 1995;346:14234.
65. Boogaard R, Smit F, Schornagel R, Vaessen-Verberne AA, Kouwenberg JM,
Hekkelaan M, et al. Recombinant human deoxyribonuclease for the treatment
of acute asthma in children. Thorax 2008;63:1416.
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003
G Model
66. Denmark TK, Crane HA, Brown L. Ketamine to avoid mechanical ventilation in
severe pediatric asthma. J Emerg Med 2006;30:1636.
67. Allen JY, Macias CG. The efcacy of ketamine in pediatric emergency department patients who present with acute severe asthma. Ann Emerg Med
2005;46:4350.
68. Buysse CM, de Jongste JC, de Hoog M. Life-threatening asthma in children:
treatment with sodium bicarbonate reduces PCO2. Chest 2005;127:86670.
69. Caroll. Heliox for children with acute asthma: Has the sun set on this therapy?
Pediatr Crit Care Med 2010;11:4289.
70. Kim IK, Phrampus E, Venkataraman S, Pitetti R, Saville A, Corcoran T, et al.
Helium/oxygen-driven albuterol nebulization in the treatment of children with
moderate to severe asthma exacerbations: a randomized, controlled trial.
Pediatrics 2005;116:112733.
71. Rodrigo G, Pollack C, Rodrigo C, Rowe BH. Heliox for nonintubated acute asthma
patients. Cochrane Database Syst Rev 2006. CD002884.
72. Walker DM. Update on epinephrine (adrenaline) for pediatric emergencies. Curr
Opin Pediatr 2009;21:3139.
73. Wiebe K, Rowe BH. Nebulized racemic epinephrine used in the treatment of
severe asthmatic exacerbation: a case report and literature review. CJEM
2007;9:3048.
74. Asthma: follow-up statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67:2468.
75. Mayordomo-Colunga J, Medina A, Rey C, Concha A, Menendez S, Arcos ML, et al.
Non-invasive ventilation in pediatric status asthmaticus: a prospective observational study. Pediatric Pulmonology 2011;46:94955.
76. Thill PJ, McGuire JK, Baden HP, Green TP, Checchia PA. Noninvasive positivepressure ventilation in children with lower airway obstruction. Pediatr Crit Care
Med 2004;5:33742.
77. Basnet S, Mander G, Andoh J, Klaska H, Verhulst S, Koirala J. Safety, efcacy, and
tolerability of early initiation of noninvasive positive pressure ventilation in
pediatric patients admitted with status asthmaticus: A pilot study. Pediatr Crit
Care Med 2012;13:3938.
78. Tobias JD. Inhalational anesthesia: basic pharmacology, end organ effects, and
applications in the treatment of status asthmaticus. J Intensive Care Med
2009;24:36171.
79. Wheeler DS, Clapp CR, Ponaman ML, Bsn HM, Poss WB. Isourane therapy for
status asthmaticus in children: A case series and protocol. Pediatr Crit Care Med
2000;1:559.
80. Shankar V, Churchwell KB, Deshpande JK. Isourane therapy for severe refractory status asthmaticus in children. Intensive Care Med 2006;32:92733.
81. Mikkelsen ME WY, Sager JS, Fuchs BD, Christie JD. Outcomes using extracorporeal life support for adult respiratory failure due to status asthmaticus. ASAIO
Journal 2009;55:4752.
82. Hebbar KB, Petrillo-Albarano T, Coto-Puckett W, Heard M, Rycus PT, Fortenberry JD. Experience with use of extracorporeal life support for severe refractory status asthmaticus in children. Crit Care 2009;13:R29.
83. Camargo CA, Rachelefsky G, Schatz M. Managing asthma exacerbations in the
emergency department. Summary of the national asthma education and prevention program expert panel report 3 guidelines for the management of
asthma exacerbations. Proc Am Thoracic Society 2009;6:35766.
Please cite this article in press as: Koninckx M, et al. Management of status asthmaticus in children. Paediatr. Respir. Rev. (2013), http://
dx.doi.org/10.1016/j.prrv.2013.03.003